INDiGO Case Study
Fast-tracked Development Despite being a BCS Class IV Drug
Poor Bioavailability, An Even Greater Risk of Costly Delays & Holdups
Learn how Evotec’s IND-enabling package helped a small US biotech quickly overcome formulation development challenges and achieve regulatory submission in only 14 months.
Key points in our case study:
- Evotec's INDiGO® IND-enabling package helped a small US biotech expedite regulatory submission of their BCS class IV drug in just 14 months
- A robust regulatory data package was delivered on schedule and within budget, despite complex bioavailability issues
- Evotec’s integrated approach ensured rapid decision-making and right-first-time results, giving the sponsor the competitive edge
Generating a quality data package against a demanding timeframe can be a challenging endeavor for any new drug. However, when your molecule exhibits poor bioavailability, there’s an even greater risk of costly delays and holdups.
View our video & download our case study!
Download the Case Study
If you wish to read our case study document, please fill out the form here. You will be redirected to a page where you can download the case study.
